2

To the editor
Histone acetylation and deacetylation is an important epigenetic regulator of gene expression.
The acetylation of histones leads to a more accessible chromatin state and enables gene transcription. Histone deacetylases (HDACs) alter gene expression by removing the acetylation of the histones, resulting in a more condensed chromatin state, which in turn leads to repressed gene transcription. Consequently, the inhibition of histone deacetylation promotes gene expression. The acetylation of histones is believed to be primarily regulated by the HDAC-1, -2 and -3 proteins 1 , which belong to the class I HDACs. Finally, HDAC inhibitor treatment reduces endothelial cell proliferation, migration and tube formation, supporting the hypothesis that the inhibitors have anti-angiogenic properties 9 .
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The effect of HDAC inhibitors in psoriasis has not yet been described, but the benefit of these compounds in other inflammatory conditions and in the modulation of inflammation, proliferation and angiogenesis after in vitro treatment makes it tempting to speculate on a possible role in the treatment of psoriasis 10 .
To investigate whether HDACs are dysregulated in psoriasis, we assayed the total HDAC activity in peripheral blood mononuclear cells (PBMCs) and skin from psoriasis patients and characterized the protein expression of HDAC-1, -2 and -3 in the psoriatic skin. PBMCs were isolated from 15 psoriasis patients and 15 healthy controls. The PBMCs were cryopreserved in liquid nitrogen until the time of the assay, when they were suspended in hypotonic buffer (10 mM EDTA, 50 mM Tris) and lysed to obtain the protein fraction.
Skin punch biopsies were obtained from 5 psoriasis patients and 5 healthy controls and were immediately stabilized in Allprotect TM reagent (QIAGEN, Hilden, Germany). Total protein was extracted by snap-freezing in liquid nitrogen, followed by mechanical disruption and lysis buffer (hypotonic buffer with 1% Triton-X). The obtained suspension was snap-frozen and stored overnight.
A total of 50 µg protein was used from each sample in an HDAC activity assay (BioVision, Milpitas, CA, USA), according to the instructions of the manufacturer. The activity assay was performed on total protein and measures the activity of all HDACs with the capacity to deacetylate histones. The resulting color intensity was measured at 405 nm and the standard supplied in the assay was used to prepare a reference curve of HDAC activity. Statistical analysis of the activity assay was performed using the Mann-Whitney test for non-parametric, unpaired samples. A p-value of less than 0.05 was considered significant. Although all samples displayed signs of HDAC activity, we observed no differences in the activity of PBMCs from psoriasis patients compared with healthy controls (Fig. 1A) . Nor did we see any difference in the activity of protein extracted from lesional psoriasis biopsies compared with healthy skin (Fig. 1B) . While the sample size is small, a prominent ant clinically relevant change in activity should be visible even in a small sample size. The diversity in response even in healthy control subjects suggests that there is a large variation in HDAC activity between individuals even when psoriasis is not a factor and that other parameters influence the activity to a greater extent than having psoriasis.
Immunohistochemical staining revealed the presence of HDAC-1 and -2 protein in both lesional psoriatic skin and healthy skin, localized primarily to the epidermis. For HDAC-3, the staining varied between individuals, but these variations were found among both healthy controls and psoriasis patients. None of the antibody stainings revealed any difference in distribution or intensity between healthy controls and psoriasis patients.
A dysregulation of HDACs has been described in a variety of diseases, including RA 4 , ankylosing spondylitis 11 , different cancer types 12 and cardiovascular disease 13 . The use of HDAC inhibitors as pharmacological treatment is an expanding field with promising results for the treatment of several of these diseases 14 . In lesional psoriatic skin, an over-expression 5 of HDAC-1 mRNA has been previously suggested 15 , but has not been confirmed at protein level. Nor has the HDAC activity in psoriasis been previously determined.
In this study we have chosen to focus on the class I HDACs because of their prominent role in histone deacetylation. We cannot draw any conclusions about whether other epigenetic mechanisms, for example methylation, have a role in psoriasis pathogenesis.
In this study, we examined the levels of total HDAC activity in blood and skin in psoriasis and investigated the protein expression of HDAC-1, HDAC-2 and HDAC-3 in the psoriatic lesion. We obtained no preclinical support for a dysregulation of HDACs in psoriasis.
This lack of difference in HDAC activity and HDAC-1, -2 and -3 protein expression between psoriatic lesions and healthy skin further suggests that HDAC inhibitors may not be a relevant treatment for this patient group. 
